Safety, Tolerability and Efficacy of VUM02 Injection in Treatment of Idiopathic Pulmonary Fibrosis (IPF)

Conditions: Idiopathic Pulmonary Fibrosis Interventions: Drug: VUM02 Injection Sponsors: Wuhan Optics Valley Vcanbiopharma Co., Ltd. Not yet recruiting

Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials